JonesResearch initiated coverage of Dyne Therapeutics (DYN) with a Buy rating and $30 price target Over the next 12 months, Dyne has two shots on goal in rare neuromuscular diseases, the analyst tells investors in a research note. The firm says the company’s “competitive edge” is the Force platform, which increases muscle delivery using an antibody fragment. It forecasts $3B in unadjusted worldwide peak sales in 2034.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYN:
- Dyne Therapeutics initiated with a Market Perform at Bernstein
- Dyne Therapeutics price target lowered to $32 from $46 at Baird
- Dyne Therapeutics: Strategic Advancements and Promising Clinical Data Drive Buy Rating
- Dyne Therapeutics’ DYNE-101 Gains Momentum with FDA Breakthrough Designation and Optimized Clinical Trials
- Dyne having vHOT as primary endpoint ‘encouraging,’ says H.C. Wainwright